Therapy Areas: Vaccines
GSK and Sanofi to make 200 million doses available for WHO's COVAX COVID-19 vaccine alliance
28 October 2020 -

French pharmaceutical company Sanofi SA (Paris:SASY) and British pharmaceutical company GlaxoSmithKline (LON:GSK) plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organisation, Reuters news agency reported on Wednesday.

According to the companies, they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan vaccine distribution plan COVAX.

COVAX aims to deliver two billion vaccine doses around the world by the end of 2021. Reportedly, more than 180 nations have joined the plan.

Currently, the GSK-Sanofi alliance has signed a USD2.1bn deal with the U.S. to supply it with more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the EU and the UK.

The first results from an early mid-stage study of the Sanofi-GSK vaccine are expected in early December 2020 and the companies plan to file for regulatory approval in 2021.